Debulking metastases of pancreatic neuroendocrine tumors may be effective at a threshold of greater than or equal to 70%, indicating that liver debulking criteria could possibly be extended to this threshold. READ MORE
Patients with pancreatic cancer formally believed to not be eligible for surgery may in fact benefit from resection.
The efficacy and safety of galunisertibi n combination with gemcitabine for the treatment of unresectable pancreatic cancer.
Debulking metastases of pancreatic neuroendocrine tumors may be effective at a threshold of greater than or equal to 70%, indicating that liver debulking criteria could possibly be extended to this threshold.
The National Comprehensive Cancer Network has released their latest guidelines for the treatment of pancreatic adenocarcinoma, featuring a new therapy in the second-line setting.
Multiple preoperative indicators may be used as prognostic markers for patients with operable pancreatic ductal adenocarcinoma.
The pancreatic cancer resectability criteria advocated by the NCCN may be more complicated than necessary.
Research in Review
Germline mutations in pancreatic cancer susceptibility genes are often identified in patients with pancreatic cancer without a known family history of cancer.
The addition of radiation therapy to chemotherapy improved overall survival in patients with unresected locally advanced pancreatic cancer.
A tyrosine kinase inhibitor with gemcitabine does not improve survival any more than gemcitabine alone for patients with advanced pancreatic cancer.
A study compared the readability and accuracy of patient-oriented online resources for pancreatic cancer by looking at treatment methods and website affiliation.